BIOMERIEUX
FREURBIOMERIEUX (US:BMXMF) — Diagnostics & Research. Antal børser, hvor selskabets aktier handles: 4. På denne side — kurs og diagram, udbytte, største aktionærer og historik over antal aktier.
Om Virksomheden
- Websted
- biomerieux.fr
- Sektor
- Healthcare · Diagnostics & Research
- Hovedkontor
- Marcy-l'Étoile, France
- Administrerende Direktør
- Pierre Boulud
- Ansatte
- 14 562
- Grundlagt
- 1963
- Udestående Aktier
- 117.95 mio.
- Free Float
- 40.02 mio.
- Markedsværdi
- 9.17 mia. EUR
- Insidere
- 66.46%
- Institutionelle Investorer
- 16.73%
- Juridisk Form
- K65D
- ISIN
- FR0013280286
- LEI
- 549300AK8Y0LBIQ4T071
- Udbetalingsgrad
- 24.9%
- FCF
- 586 mio. EUR
- Udbetaling / FCF
- 20%
- Gæld
- 422 mio. EUR0.0 år FCF
- Udbyttestreak
- 21 år
- Indtjening, FCF og udbetalt udbytte — for de 12 måneder frem til 30.06.2026 (selskabets seneste rapport).
Beskrivelse
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL, a rapid AST system; ETEST, a gradient method on culture media; BIOMERIEUX EPISEQ CS, a whole genome sequencing solution for epidemiologic monitoring; VIDAS, a specific marker of severe bacterial infections/sepsis; and Biomérieux vision suite, a software that provides information to support diagnosis and clinical decision making. It also provides culture media and associated instruments; ARGENE that provides PCR tests for diagnosing viral respiratory diseases; EMAG system and NUCLISENS extraction reagents for DNA and RNA extraction; GENE-UP and VERIFLOW for detection of microorganisms for the food industry; ETEST for manual measurement of minimum inhibitory concentration of an antibiotic; API and RAPIDEC CARBA NP for identification of bacteria and manual antimicrobial susceptibility testing; BIOBALL for quantitative microbiological quality control; CHEMUNEX, a microbiology instrument; ENDONEXT for detection of endotoxins; TEMPO for fluorescence counting of bacteria; and Hybiome, a CLIA technology, as well as lab consultancy service and training modules. The company was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. operates as a subsidiary of Institut Mérieux SA.
Udbytte
BIOMERIEUX (BMXMF) udbetaler udbytte én gang om året. Pr. År (12 måneder op til og med den senest annoncerede betaling): 0.98 EUR pr. Aktie (betalinger: 1). Baseret på betalingshistorikken forventes næste ex-udbyttedato omkring 10.06.2027. Uafbrudt udbyttehistorik: 21 år.
| Ex-Dato | Udbetaling | Beløb | % | Type | Ticker |
|---|---|---|---|---|---|
| 2026-06-10 | 2026-06-11 | 0.9800 EUR | 1.3/1.3 % | årlig | US:BMXMF |
| 2025-06-10 | 2025-06-11 | 0.9000 EUR | 0.7/0.7 % | årlig | US:BMXMF |
| 2024-06-10 | 2024-06-11 | 0.8500 EUR | 0.9/0.9 % | årlig | US:BMXMF |
Største Ejere
| Ejer | Andel | Aktier | Rapportdato |
|---|---|---|---|
| New Economy Fund | 0.86% | 1.02 mio. | 2026-06-30 |
| VANGUARD STAR FUNDS-Vang… | 0.54% | 638 380 | 2026-04-30 |
| Tweedy, Browne Fund Inc.… | 0.41% | 481 731 | 2026-06-30 |
| VANGUARD TAX-MANAGED FUN… | 0.32% | 384 560 | 2026-06-30 |
| iShares Trust-iShares Co… | 0.26% | 304 380 | 2026-07-31 |
| AMERICAN FUNDS INSURANCE… | 0.19% | 226 573 | 2026-06-30 |
| Fidelity Concord Street… | 0.13% | 149 019 | 2026-07-31 |
| Bridge Builder Trust-Bri… | 0.12% | 142 421 | 2026-06-30 |
| iShares Trust-iShares MS… | 0.12% | 142 244 | 2026-07-31 |
| DFA INVESTMENT TRUST CO-… | 0.09% | 109 829 | 2026-04-30 |
| Pacer Advisors, Inc. | 0% | 202 | 2026-06-30 |
